forzinity company: Stealth BioTherapeutics Research Profile
Disclaimer: All content on this site is based on public academic research and clinical data for educational and informational reference only. It is not medical advice. No treatment or health-related decisions should be made based solely on website content. This site does not sell pharmaceuticals or endorse any medical treatment.
Who owns forzinity
forzinity's brand holder and developer is Stealth BioTherapeutics, a clinical-stage biotechnology company built around mitochondrial medicine. The company carried elamipretide — under its development names MTP-131 and Bendavia — through more than a decade of clinical programs before the September 2025 accelerated approval made forzinity the company's first approved product. Public corporate filings and the company's own disclosures are the primary sources for this page.
Ownership questions in pharma have two layers: the brand owner (Stealth BioTherapeutics in the U.S.) and the territorial licensees — most notably Pharmanovia, which holds European rights with an EMA decision anticipated around mid-2027 per public reporting. The regulatory implications of that structure are summarized on our forzinity fda page, and the market-access consequences on the cost pillar.
The elamipretide pipeline history
The public pipeline record is a study in persistence: primary mitochondrial myopathy (MMPOWER-3), heart failure (PROGRESS-HF), dry age-related macular degeneration (ReCLAIM) — all completed without meeting primary endpoints — before Barth syndrome (TAZPOWER) delivered the approval. The full trial map is on the clinical trials pillar; the corporate lesson is that the approved indication was the program's narrowest and most mechanistically direct population.
For company research purposes, that history is the useful signal: a developer whose late-stage record shows honest nulls in broad populations and a success in a genetically-defined rare disease is a different risk profile than a company that never published the nulls. We grade corporate claims with the same evidence tiers as scientific ones, per our editorial policy.
Commercial structure around the brand
The commercial architecture that public reporting describes for forzinity is deliberately narrow: a specialty-pharmacy channel through AnovoRx, a manufacturer support program (Mito Assist, documented on our patient assistance page), and list-price data at roughly $59,636 per 14 mL supply. The economics behind that structure — orphan-drug pricing and the single-channel distribution model — are analyzed in the cost pillar.
A note on the distinction this site maintains: profiling a company from public documents is not an endorsement. Our disclaimer applies; nothing here assesses investment merit, and nothing here vouches for any commercial channel. The related question — how the regulated brand relates to research-grade ss-31 suppliers — is handled separately on the forzinity vs ss-31 comparison page.
How to verify corporate information about forzinity
Corporate claims in this topic space drift fast: press paraphrases get simplified, aggregator profiles go stale after funding events, and SEO pages invent ownership details outright. The checkable chain is: the FDA approval database (owner of record for the application), the company's own disclosures, and dated trade reporting — in that order. Our forzinity website resources page maps the official sources.
The practical test for any third-party profile, including ours: does it date its claims and name its sources? This page's parameter table does exactly that, and the same structure repeats across the forzinity cluster rooted in the forzinity pillar.
How to use the data on this page
Step 1 — extract the parameters. Extract the corporate parameters with their dates: who holds the brand, who holds which territorial licenses, what the pipeline record shows and when each fact was current. Ownership facts about pharma companies expire — note collection dates alongside each.
Step 2 — normalize before comparing. Normalize by jurisdiction: U.S. brand ownership, European licensing and research-grade supply are three different corporate geographies that only look like one question. Convert each ownership claim to its source document (approval record, license announcement, corporate filing) before comparing.
Step 3 — grade the source. Grade the source: regulatory databases and corporate disclosures outrank trade reporting, which outranks aggregators, which outrank SEO-generated profile pages. Where a profile cannot be traced to a document, discard it.
Parameter comparison
forzinity corporate and ownership parameters as public documents describe them.
| Parameter | Public record | Source tier |
|---|---|---|
| Brand owner / developer | Stealth BioTherapeutics | Regulatory + corporate disclosures |
| Approved product | forzinity (elamipretide), FDA accelerated approval 2025-09-19 | FDA record |
| European rights | Licensed to Pharmanovia; EMA decision anticipated mid-2027 | Public reporting / license announcement |
| Specialty pharmacy channel | AnovoRx | Public reporting |
| Support program | Mito Assist (833-458-9099) | Program documentation |
| Development code names | elamipretide / ss-31 / MTP-131 / Bendavia / 2S50 | Literature + catalog records |
Table: forzinity corporate and ownership parameters as public documents describe them. — compiled from public regulatory and academic sources; verify against the original documents before use.
Frequently asked questions
Who owns forzinity?
Stealth BioTherapeutics, the clinical-stage mitochondrial-medicine company that developed elamipretide. European rights are licensed to Pharmanovia. This profile summarizes public documents only and is not an endorsement.
Is forzinity made by a big pharma company?
No. The public record describes Stealth BioTherapeutics as a clinical-stage biotechnology company; forzinity is its first approved product, distributed through a specialty-pharmacy channel rather than a broad-pharma commercial infrastructure.
References
- FDA approval record for forzinity (elamipretide), accessdata.fda.gov.
- Stealth BioTherapeutics corporate disclosures and press releases (public).
- Pharmanovia license announcement and European regulatory reporting (public).
- Trade and specialty-pharmacy reporting on AnovoRx distribution (2025–2026).